At the final follow-up, immunofluorescence analysis evidenced that EMBs fromT2DMrecipients in poor glycemic control showed higher expression of ACE2 in cardiomyocytes than non-T2DM recipients and T2DM recipients in good glycemic control (Fig. 4). Here, ACE2 is linked to type 2 diabetes mellitus.